Corixa/GSK Bexxar
Executive Summary
Corixa and GlaxoSmithKline submit data to FDA Aug. 8 in response to March 16 "complete review" letter for radioimmunotherapy Bexxar (tositumomab). Resubmission addresses FDA's concerns on chemistry, manufacturing and controls and issues raised about the clinical section of the BLA, the companies said